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ABSTRACT                                                                                                                                                                                                           
Monkey pox infection is a zoonotic infection transmitted by direct or indirect contact with blood, body fluids and lesions of 
an infected animal. Human to human spread of Monkey pox has been described and infection is usually self-limiting, with 
an incubation period of 6-16 days. In Nigeria, the last case of monkey pox infection was recorded over 46 years ago. The 
recent emergence in Nigeria occurred in the year 2017 and was reported to have spread to 24 states with 228 suspected 
individuals affected. Laboratory diagnosis, as well as management and prevention of monkey pox infection in Nigeria, 
remain challenging as Nigeria is a resource-poor country with limited infrastructure, technical skill and training which is 
required in making a diagnosis. The ability of the monkey pox virus to evolve, its potential bioterrorism potential, as well 
as its recent emergence in Nigeria further justifies the need for improving the understanding of the presentation and 
prevention of monkey pox infection. 
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Résumé                                                                                                                                                                                                                                 
Infection au virus de la variole du singe est une infection zoonotique transmise par contact direct ou indirect avec du sang, 
des liquides organiques et des lésions d'un animal infecté. Homme à homme propagation de la variole du singe a été décrit 
et l'infection est habituellement auto-limitation, avec une période d'incubation de 6 à 16 jours. Au Nigeria, le dernier cas 
d'infection au virus de la variole du singe a été enregistré plus de 46 ans. L'apparition récente dans le Nigeria s'est produite 
dans l'année 2017 et se serait étendue à 24 membres avec 228 individus présumés affectés. Le diagnostic de laboratoire, ainsi 
que la gestion et la prévention de l'infection au virus de la variole du singe au Nigeria, sont ambitieux que le Nigeria est un 
pays pauvre en ressources avec une infrastructure limitée, la compétence technique et de la formation qui est nécessaire 
pour faire un diagnostic. La capacité de la variole du singe Virus à évoluer, son potentiel potentiel bioterrorisme, ainsi que 
sa récente apparition au Nigeria est une raison supplémentaire de la nécessité d'améliorer la compréhension de la 
présentation et la prévention de l'infection au virus de la variole du singe. 
Mots-clés : virus, virus émergents, le Nigeria, l'éruption, zoonose, orthopoxvirus 
ABSTRACT                                                                                                                                                                                
Monkeypox infection is a zoonotic infection transmitted by direct or indirect contact with blood, body fluids and 
lesions of an infected animal. Human to human spread of Monkeypox has been described and infection is 
usually self-limiting, with an incubation period of 6-16 days. In Nigeria, the last case of monkeypox infection was 
recorded over 46 years ago. The recent emergence in Nigeria occurred in the year 2017 and was reported to have 
spread to 24 states with 228 suspected individuals affected. Laboratory diagnosis, as well as management and 
prevention of monkeypox infection in Nigeria, remain challenging as Nigeria is a resource-poor country with 
limited infrastructure, technical skill and training which is required in making a diagnosis. The ability of the 
monkeypox virus to evolve, its potential bioterrorism potential, as well as its recent emergence in Nigeria further 
justifies the need for improving the understanding of the presentation and prevention of monkeypox infection 
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INTRODUCTION                                                                                                                                                                                    
Monkeypox is a relatively rare viral zoonotic 
infection which occurs primarily in remote parts of 
Central and West Africa, especially in the rural 
rainforest regions of Congo Basin and Democratic 
Republic of Congo, where it is considered to be 
endemic. It was first identified in 1958 during an 
investigation of a pox-like disease among monkeys 
in the State Serum Institute in Copenhagen, 
Denmark hence its name (1). The first case of 
human monkeypox infection was first described in 
a 9-year-old boy from Equateur province of Zaire, 
Democratic Republic of Congo, Central Africa, who 
developed a smallpox-like illness which was later 
confirmed as human monkeypox by World Health 
Organization  (2).  
Monkeypox virus is an oval brick-shaped virus 
with double-stranded DNA, which belongs to the 
Poxviridaefamily,thesubfamily; Chordopoxvirinae 
and genus Orthopoxvirus. Other members of the 
family include Variola virus, Vaccinia virus (the 
virus used in smallpox vaccine), Cowpox virus, 
Camelpox virus and Ectromelia virus3. Since the 
eradication of smallpox, monkeypox is the foremost 
Orthopoxvirus affecting man (4). There are two 
distinct clades of Monkeypox virus namely the 
Congo Basin and the West African clades; The 
Congo Basin clade is more virulent and has a higher 
rate of human-to-human transmission4–6. 
The recent outbreak of monkeypox in Nigeria 
which spanned October 2017 to February 2018 was 
a source of public health concern. There was an 
initial diagnostic dilemma as many individuals; 
physicians inclusive had no knowledge of the 
aetiology of the disease condition. The Centre for 
Disease Prevention and Control (CDC) played a 
vital role in diagnosis, as well as implementation of 
treatment plan, prevention and control.  
Monkeypox virus is a potential agent of 
bioterrorism as it is second to Variola virus, the 
agent of smallpox in terms of orthopoxvirus 
virulence with a mortality rate of 10% (3,5). Hence, 
there is an urgent need to educate physicians and 
the general public on the diagnosis, management 
and control of this disease.   
Biology of Monkeypox virus 
Monkeypox virus is an enveloped zoonotic virus 
and a species of the genus Orthopoxvirus in the 
family Poxviridae. It has a similar morphology, 
size, and genome to Variola virus; however, it has a 
very broad host range, making it capable of 
infecting many species such as rodents, monkeys, 
and humans. This has allowed the virus to persist 
in wild host reservoir, causing sporadic human 
diseases thus avoiding global eradication by 
vaccination. The monkeypox virus measures about 
200-250nm in size, it appears brick shaped, with 
characteristic surface tubules and a dumb bell 
shaped core. Its genome is approximately 199 kb of 
double stranded linear DNA and contains 
approximately 190 non-overlapping Open reading 
frame (ORFs) >180 nt long (1,7-9,26). Like all 
orthopoxviruses, the central coding region sequence 
(CRS) at monkeypox virus nucleotide positions 
56000–120000 is highly conserved and flanked by 
variable ends that contain inverted terminal repeats 
(ITRs). At present, there are virtually no studies of 
the biology of the monkeypox virus as there have 
been no animal models in which to study 
monkeypox. 
EPIDEMIOLOGY                                                                                                                 
Monkeypox is indigenous to the rainforests of 
Central and West Africa. Between 1970 and 1986, 10 
cases of human monkeypox infection were reported 
in Sierra Leone, Nigeria, Liberia and Cȏte d’Ivoire 
all (5). A total of 338 cases were reported from 
surveillance reports from 1981 to 1986 in the 
Democratic Republic of Congo. Another outbreak 
occurred from 1996-1997 in the Democratic 
Republic of Congo, with an attack rate of 22 cases 
per 1000 population, sporadic occurrences in 
neighbouring countries have also been reported (5). 
The first report of human monkeypox infection 
outside Africa occurred in 2003 in the United States 
following shipment of rodents imported from 
Ghana to Texas. Eighty-one (41% laboratory 
confirmed) cases of monkeypox were reported in 
this outbreak (6). In 2003, 11 cases of monkeypox 
and 1 death were reported from the Democratic 
Republic of Congo while in 2005, 10 cases were 
reported in Sudan. 
Between September and December 2017, Nigeria 
reported 89 confirmed and 228 suspected cases of 
monkeypox from 24 out of the 36 states in the 
country (10). Studies of monkeypox virus have 
identified at least 2 different genetic types (clades) 
of the virus, both of which segregate based upon 
geographic separation, with one type being found 
in West Africa and the other in Central Africa 
(11). The West African clade was implicated in this 
outbreak. Most of the confirmed cases were among 
adults whose ages ranged from 21- 40 years with 
male to female ratio of 2.5:1. Six deaths were 
reported among which four reportedly had 
background immunosuppressive illness (10,12.)  
Prior to this, only 3 cases had been previously 
reported in Nigeria. The first reported case 
occurred in 1971, in a 4-year-old boy from the South 
Eastern part of the country while the last reported 
case occurred in 1978 (13). Prior to the recent 
outbreak, there had been no reported case of 
monkeypox in Nigeria since 1978.  Another West 
African country, Liberia has also reported 2 
confirmed cases of monkeypox in November 2017 
14).  
In endemic countries, transmission occurs all 
through the year without peak month or season 
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(15). Incidence of monkeypox infection is equal in 
males and females with no racial predilection. In 
epidemics seen in Africa, children less than 15 years 
of age were the most affected and this might be 
linked to the cessation of smallpox vaccination (16).  
Pathogenesis 
Transmission to humans occurs via handling of 
infected animals, direct contact with the blood, 
body fluids, inoculation from mucocutaneous 
lesions on an infected animal, especially when the 
skin barrier is lost due to scratches, bites or other 
trauma or ingestion of inadequately cooked meat of 
infected animals (5,15). Transmission has been 
documented through handling of infected 
monkeys, Gambian giant squirrels, rats, rabbits, 
dormice, porcupines, gazelles and prairie dogs (5). 
Outbreaks typically occur among inhabitants of 
small villages involved in hunting and gathering 
with close physical contact being the most 
significant risk factor for monkeypox infection. No 
animal has been identified as its exact natural 
reservoir however, rodents are being considered. 
Person to person transmission can occur via large 
respiratory droplets during prolonged face-to-face 
contact. Congenital monkeypox infection can also 
occur via placental transmission (5) .  
Monkeypox infection begins with infection of the 
dermis or respiratory epithelium following 
transmission from infected animals or person 
respectively. Dissemination of the virus occurs 
through the lymphatics to the blood with resultant 
primary viraemia and systemic infection. Secondary 
viraemia occurs and results in infection of the 
epithelium with resultant skin and mucosal lesions. 
Replication of the virus in mucosal surfaces can 
result in its transmission via oropharyngeal 
secretions to close contacts (15). In spite of the host 
immune response, the density of virus in 
oropharyngeal secretions, proximity and duration 
of contact and virus survival likely affects the risk 
of transmission of the virus as the monkeypox virus 
has evolved mechanisms of evading the host 
immune response (15).  
Clinical manifestations 
Monkeypox has an incubation period which ranges 
from 4 to 21 days with an average of 6 to 16 days. 
This is followed by a prodromal illness which lasts 
for 1 to 5 days. Typical characteristics of the 
prodromal illness include fever (38.5-40.5℃), 
malaise, intense headache, lymph node 
enlargement, back pain, myalgia and intense 
asthenia (4,16). The prodromal phase is also known 
as the pre-eruptive phase and an individual may be 
infectious during this phase. Rashes appear within 
1 to 10 days of development of fever, this is known 
as the eruptive or exanthema phase. The rash 
usually begins on the face and then spread to other 
parts of the body, the palms and the soles may also 
be affected. Affectation of the face is seen in 95% of 
cases (17).  The lesions seen in monkeypox are 
extremely similar to that of smallpox: they appear 
monomorphic, hard and pea-sized on an 
erythematous base; often described as “dew drops 
on a rose petal”18. However, unlike smallpox, the 
lesions may appear in crops and do not have a 
strong centrifugal spread (5).  
The sequence of appearance of the rash is as 
follows; macules, papules, vesicles and pustules 
involving both covered and uncovered areas. The 
rash evolves synchronously over 14 to 28 days, 
usually between 1-10 days after the onset of fever 
(3,5). Some of the lesions may have a central 
umbilication. The lesions of chickenpox occur in 
successive crops with various stages of 
development being visible at any time hence aiding 
its differentiation from that of monkeypox, as these 
are usually in one stage of development and slowly 
progress to the next stage with each stage lasting 1-
2 days (4,17). Lesions may be few to several 
thousands in number, with affectation of the oral 
mucosa, genitalia and conjunctiva in 70%, 30% and 
20% of cases respectively. Corneal affectation has 
also been described. Pruritus may be seen as well as 
petechiae and ulceration, pain is unusual.  Crusting 
of the rash is seen in about 10 days after its onset 
and complete disappearance observed within 2-4 
weeks of onset (17). An individual is infectious 
from the onset of exanthem through to the crusting 
of the rash. Fever subsides within 1-3 days after the 
onset of the rash, however, a second febrile period 
has been described when the lesions become 
pustular and this has been linked with deterioration 
in the general condition of the patient (4.)  
Other symptoms seen include chills and/or 
drenching sweats, severe headache, backache, 
pharyngitis, myalgia, cough and shortness of 
breath. Enlargement of the submental, 
submandibular and cervical or inguinal lymph 
nodes is a common feature. The lymph nodes 
appear firm and sometimes tender. The presence of 
lymph node enlargement is a key feature in 
differentiation of monkeypox from smallpox and 
chickenpox, as it is a rare feature in smallpox while 
it is seen in 90% of unvaccinated patients with 
monkeypox infection4,5,17. Pitted scars and/or areas 
of hypo/hyperpigmentation may persist after 
crusts have fallen (12,19).  
Typically, human monkeypox infection is a self-
limiting illness which lasts for 14-21 days. Severe 
cases are seen in children and may require intensive 
care and are usually related to the extent of virus 
exposure, health status, vaccination status, 
comorbidities and severity of complications (5,17). 
Individuals previously vaccinated against smallpox 
have a milder form of the disease as they have 
fewer and smaller lesions, less lymphadenopathy 
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and generally less severe disease (4,16). Conditions 
which suppress cell-mediated immunity such as 
HIV may alter the natural history of the disease and 
may result in more severe infections (15). The 
lesions seen in them are also noticed to have 
regional monomorphism and a centrifugal 
distribution. Lesions in children may appear as 
nonspecific 1-5 mm erythematous papules, 
resembling an arthropod bite reaction. Mortality 
rates range from 1 to 10% with most cases occurring 
in children and in unvaccinated persons (16). 
Indirect or low-level exposure may result in 
asymptomatic or subclinical infections especially in 
persons living in or beside forests. Complications of 
monkeypox infection include pitted scars, 
deforming scars, secondary bacterial infection, 
keratitis, corneal ulceration, blindness, 












Figure 1: A child affected by monkeypox, showing 
generalized vesiculo-pustular rashes involving the 
trunk, limbs, face and limbs, extending to the palms and 
soles of the feet. Photo was reproduced from Centres for 
Disease Control and Prevention 
(https://www.cdc.gov/poxvirus/monkeypox/index.html)  
Laboratory diagnosis 
Diagnosis of monkeypox infection is made by cell 
culture, polymerase chain reaction (PCR), enzyme-
linked immunosorbent assay (ELISA) or Western 
blotting with PCR being used for definitive 
diagnosis3–5,18. Standard, contact and droplet 
precautions must be applied during specimen 
collection and all samples potentially infected with 
monkeypox virus should be handled in Biosafety 
level 2 facilities. Specimen that may be obtained to 
aid diagnosis include tonsillar tissue, 
oropharyngeal tissue or nasopharyngeal tissue 
swab, lesion biopsy using the punch biopsy kit, 
lesion fluid, lesion roof, scab/crust, whole blood, 
acute and convalescent phase sera (4–6,16). 
Oropharyngeal or nasopharyngeal swab can be 
obtained for viral culture using MK2 cells, LLC-
MK2 cells and Vero E6 cells. Growth is detected by 
the presence of cytopathic effects which is seen as 
multinucleated syncytial keratinocytes. However, 
this cytopathic effect is also seen with Vaccinia and 
Cowpox viruses thereby causing a difficulty in 
differentiating these viruses via cell culture. The 
virus can be identified from the culture by DNA 
restriction analysis (5). 
Exudates of the lesion on a swab, scabs of the 
lesion, skin biopsy of the vesiculopustular rash or a 
sample of the roof of an intact vesiculopustule can 
also be used for diagnosis. These can be analysed 
using PCR for DNA sequence-specific for 
monkeypox virus such as the monkeypox 
extracellular-envelope virus protein gene and the 
conserved segment of the DNA polymerase gene 
(E9L) (19,20). Maintenance of a cold chain upon 
specimen collection is preferable but if cold chain is 
unavailable, the viral DNA in the specimen is stable 
for a long time if kept in a cool, dark environment. 
Detection of antibodies; immunoglobin M (IgM) or 
immunoglobin G (IgG) in serum or plasma using 
ELISA is an effective means of diagnosis of 
monkeypox infection (21). IgM is detected in serum 
about 5 days after the onset of rash while IgG is 
detected after more than 8 days of the onset of rash. 
Paired sera for IgG and IgM titers may be analyzed 
for increasing titre values to detect seroconversion 
which is used as an indicator of recent monkeypox 
infection (21). Tzanck smear can be used to 
differentiate monkeypox infection from other non-
viral disorders but it does not differentiate 
monkeypox infection from smallpox or herpetic 
infections. Antibody Immuno Column for 
Analytical Processes (ABICAP), an immune-
filtration technique which works based on gravity-
driven flow-through antigen capture ELISA has 
been developed. It is an on-site laboratory 
diagnostic test which can be used in both humans 
and animals (22).  
Biopsy specimen from lymph nodes or scab 
material; vesicular fluid, blood specimen or viral 
culture can be examined using electron microscopy 
with negative staining revealing a large brick-
shaped particle with rounded corners which is 
characteristic of a poxvirus (18). Round-to-oval 
intracytoplasmic inclusions with sausage-shaped 
structures centrally measuring about 200-300 µm 
may also be seen on electron microscopic 
examination. These inclusions are commonly found 
with Orthopox viruses thereby aiding 
differentiation from Herpes and Parapox viruses 
(5). 
Histological examination of papules may reveal 
acanthosis, individual keratinocyte necrosis and 
basal vacuolation along with a superficial and deep 
perivascular, lymphohistiocytic infiltrate in the 
dermis (5,20). Histology of the vesicles may reveal 
spongiosis with ballooning and reticular 
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degeneration.  Pustules may reveal necrosis of the 
epidermis with numerous eosinophils and 
neutrophils, with many displaying karyorrhexis.  
The necrosis may extend through the entire 
thickness of the epidermis with a sharp lateral 
demarcation from adjacent intact epidermis. An 
associated perivascular infiltrate consisting of 
eosinophils and neutrophils in addition to 
lymphocytes and histiocytes may indicate 
secondary vasculitis. Presence of viral inclusions 
may be suggested by the presence of amphophilic 
intranuclear structures within the keratinocytes5. 
Eosinophilic Guarnieri-type intracytoplasmic 
inclusions are also seen within the keratinocytes 
(20). Orthopox viral antigens can be assessed using 
immunohistochemistry staining but its availability 








Figure 2: Electron micrograph of monkeypox virus. 
Reproduced from: 
http://www.uwlax.edu/clinmicro/clinicalmicro.htm 
University of Wisconsin-La Crosse, Microbiology 
program (No Author Specified). 
 Case Management 
Monkeypox is self-limiting hence treatment is 
mainly by bed rest and supportive care. However, 
hospitalization and possible intensive care may be 
necessary in severe cases. Preferably, nursing 
should be done in a negative pressure room while 
applying airborne and contact precautions to limits 
its spread. Isolation of infected individuals is also a 
necessary precaution in preventing the spread of 
the infection and this must be continued until the 
last crust is shed as direct contact with skin lesions 
and fomites are considered infectious (6). 
There is no proven treatment for human infection at 
the moment but cidofovir and brincidofovir (CMX-
001) have been shown to have anti-monkeypox 
viral activity in vitro and in animal studies (3,6). A 
reduction in mortality was observed with the use of 
cidofovir than therapeutic use of smallpox vaccine 
following intratracheal infection of cynomolgus 
monkeys (23). However, CDC recommends 
consideration of cidofovir in individuals with 
severe monkeypox infection; brincidofovir has an 
improved safety profile over cidofovir as it has less 
renal toxicity during its use in the treatment of 
cytomegalovirus infection. Tecovirimat (previously 
known as ST-246) is an oral antiviral agent with 
activity against orthopoxviruses including 
monkeypox in vitro and in animal studies but its 
effectiveness in humans is unknown (24).  
Vaccinia Immune Globulin (VIG) is a blood product 
which is rich in antibodies against Vaccinia virus; it 
is obtained from pooled blood of individuals who 
have been inoculated with the smallpox vaccine. 
There is no available data on the effectiveness of 
VIG on the prevention and treatment of 
complications from monkeypox infection, however 
its use may be considered in patients with severe 
infection15. CDC recommends the prophylactic use 
of VIG in persons who have been exposed to the 
virus but have severe cellular immunodeficiency 
with contraindication to smallpox vaccination (6).  
Prevention and Control 
Restriction of movement of monkeys and small 
African mammals may limit the spread of 
monkeypox virus outside Africa6,25. Animals with 
suspected monkeypox infection which may be 
demonstrated as rhinorrhea, respiratory distress, 
mucocutaneous lesions, ocular discharge and/or 
lymphadenopathy should be quarantined while 
avoiding contact especially bites and scratches and 
exposure to body fluids and secretions. Animals 
that might have come in contact with an infected 
animal must be quarantined and observed for 
symptoms of monkeypox for 30 days. Use of gloves 
and wearing of protective clothing while handling 
sick animals or during slaughtering procedures, 
thorough cooking of all animal products before 
eating also limits the risk of infection6,25. There is 
need to avoid contact with any material that has 
been in contact with infected animal, practicing 
good hand hygiene after contact with infected 
animals or persons also limits the risk of infection 
and its spread (5). 
There is currently no commercially available 
vaccine specific for monkeypox. Immunization of 
healthcare workers and those exposed to their 
samples with the smallpox vaccine such as 
ACAM2000, which contains live Vaccinia virus 
confers 85% protection from monkeypox infection4. 
Subsequent monkeypox infection may be milder 
even several years post vaccination with a 
reduction in the incidence of complications (16). 
The investigational vaccines Aventis Pasteur 
Smallpox Vaccine (APSV) which contains a 
replication-competent Vaccinia virus and 
Imvamune (MVA-BN): a replication-deficient 
smallpox vaccine which contains an attenuated live 
virus are also available but have restricted use6. 
Imvamune may be used in individuals with certain 
immune deficiencies. The vaccine, LC16m8 which 
also contains attenuated vaccinia virus and has less 
adverse effects than ACAM2000 has been licensed 
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for used in Japan (4.) Prior vaccination with 
vaccinia virus is known to provide 85% protection 
and reduce the severity of the infection but caution 
is needed in population with high HIV 
prevalence3,4. The discontinuation of the general 
smallpox vaccination and the ability of the virus to 
evolve may have contributed to increased 
susceptibility of humans to monkeypox infection 
(4,15).    
In the case of significant unprotected exposure to an 
infected animal or person, CDC recommends pre-
exposure smallpox vaccination to field 
investigators, laboratory personnel, veterinarians, 
and healthcare workers investigating or caring for 
patients with suspected monkeypox. Additionally, 
post-exposure smallpox vaccination within two 
weeks of exposure preferably within 4 days of 
exposure is preferable (6). Due to the relative rarity 
of monkeypox infection, vaccination of an entire 
population is uncommon and caution must be 
applied when considering vaccination in 
populations with high prevalence of HIV infection 
due to the risk of complications (5). 
Challenges with Diagnosis, Management and 
Prevention of Monkeypox in Nigeria 
It is over 46 years since the first case report of 
monkeypox in Nigeria, however there is still 
limited public awareness of the disease. Laboratory 
diagnosis, as well as management and prevention 
of monkeypox infection in Nigeria remain 
challenging. Nigeria is a resource-poor country 
with limited infrastructure, technical skill and 
training which is required in making a diagnosis. 
This might be attributed to the relative rarity of the 
disease as well as poor political willpower in 
health-related matters. There is a need to increase 
public awareness among the populace, physicians 
inclusive by dissemination of accurate information 
through authentic platforms on the risk factors, 
symptoms, signs, prevention and control of the 
disease.  Emphasis should be made on contact 
precautions while handling animals and thorough 
cooking of animals before ingestion. There is also a 
need to clarify myths about monkeypox disease in 
the various communities and states. Furthermore, 
access to basic health care should be provided for 
all through health insurance schemes in order to aid 
early diagnosis, treatment and control of the 
infection. Improvement of political willpower in 
health-related matters via policy making, provision 
of funds for infrastructure, personnel training and 
research is also necessary. Development of a field-
deployable point-of-care test further aiding the 
diagnosis is important. 
CONCLUSION                                                                                                  
In conclusion, monkeypox virus infection is 
relatively rare and usually self-limiting. In the era 
of globalization, with consequent increased 
mobility of man and cross-border transport of 
animals, there is a potential for the spread of 
monkeypox virus to several parts of the world. The 
ability of the virus to evolve, the potential threat of 
its use in bioterrorism, as well as its re-emergence 
in Nigeria further justify the need for better 
understanding of monkeypox infection. 
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